MBMarijke Bryckaert

Marijke Bryckaert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marijke Bryckaert has a total of 290 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A gain‐of‐function filamin A mutation in mouse platelets induces thrombus instability

    by Frédéric Adam, Alexandre Kauskot, Lamia Lamrani, Jean Solarz, Christelle Soukaseum, Christelle Repérant, Cécile V. Denis, Hana Raslova, Jean‐Philippe Rosa, Marijke Bryckaert


  • Open Access

    New insights into regulation of αIIbβ3 integrin signaling by filamin A

    by Lamia Lamrani, Frédéric Adam, Christelle Soukaseum, Cécile V. Denis, Hana Raslova, Jean‐Philippe Rosa, Marijke Bryckaert


  • Open Access

    New Insight into Regulation of αIIbβ3 Integrin Signaling by Filamin A

    by Lamia Lamrani, Frédéric Adam, Christelle Soukaseum, Cécile V. Denis, Hana Raslova, Jean-Philippe Rosa, Marijke Bryckaert

    Filamin (FLN) regulates many cell functions through its scaffolding activity cross-linking cytoskeleton and integrins. FLN was shown to inhibit integrin activity, but the exact mechanism remains unclear. Here, we report on the regulation of platelet integrin αIIbβ3 signaling by the FLNa subtype. Three FLNa deletion mutants were overexpressed in the erythro-megakaryocytic leukemic cell line HEL: Del1 which lacks the N-terminal CH1-CH2 domains mediating the FLNa-actin interaction; Del2 lacking the immunoglobulin-like (Ig) repeat 21 which mediates the FLNa-β3 interaction; and Del3 lacking the C-terminal Ig repeat 24, responsible for FLNa dimerization and interaction with the small Rho GTPase involved in actin cytoskeleton reorganisation. Fibrinogen binding to HEL cells in suspension and talin-β3 interaction in cells adherent to immobilized fibrinogen were assessed using the PKC agonist (phorbol 12-myristate 13-acetate) also to activate αIIbβ3. Our results show that FLNa-actin and FLNa-β3 interactions negatively regulate αIIbβ3 activation. Moreover FLNa-actin interaction represses Rac activation, contributing to the negative regulation of αIIbβ3 activation. In contrast, the FLNa dimerization domain which maintains Rho inactive, was found to negatively regulate αIIbβ3 outside-in signaling. We conclude that FLNa negatively controls αIIbβ3 activation by regulating actin polymerization and restraining activation of Rac, as well as outside-in signaling by repressing Rho.


  • Filamin A: key actor in platelet biology

    by Jean-Philippe Rosa, Hana Raslova, Marijke Bryckaert

    Filamins (FLNs) are large dimeric actin binding proteins regulating actin cytoskeleton remodeling. In addition FLNs serve as scaffolds for signaling proteins such as tyrosine kinases, GTPases or phosphatases, as well as for adhesive receptors such as integrins. They thus connect adhesive receptors to signaling pathways and to cytoskeleton. There are 3 isoforms of FLNs (FLNa, FLNb, FLNc) originating from 3 homologous genes. FLNa has been the recent focus of attention because its mutations are responsible for a wide spectrum of defects, called filaminopathies A, affecting brain (peri-ventricular nodular heterotopia or PVNH), heart (valve defect), skeleton, gastro-intestinal tract or more recently, the megakaryocytic lineage. This review will focus on the physiological and pathological role of FLNa in platelets. Indeed, FLNa mutations alter platelet production from their bone marrow precursors, the megakaryocytes, yielding giant platelets in reduced number (macrothrombocytopenia). In platelet per se, FLNa mutations may either lead to impaired alphaIIbbeta3 integrin activation or in contrast, increased alphaIIbbeta3 activation, potentially enhancing the risk of thrombosis. Experimental work delineating the interaction of FLNa with its platelet partners, including alphaIIbbeta3, the von Willebrand receptor GPIb-IX-V, the tyrosine kinase Syk and the signaling pathway of the collagen receptor GPVI will also be reviewed.


  • Open Access

    Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity

    by Alessandro Donada, Nathalie Balayn, Dominika Sliwa, Larissa Lordier, Valentina Ceglia, Francesco Baschieri, Cyril Goizet, Rémi Favier, Lucie Tosca, Gérard Tachdjian, et al.

    Filamin A (FLNa) links the cell membrane with the cytoskeleton and is central in several cellular processes. Heterozygous mutations in the X-linked FLNA gene are associated with a large spectrum of conditions, including macrothrombocytopenia, called filaminopathies. Using an isogenic pluripotent stem cell model derived from patients, we show that the absence of the FLNa protein in megakaryocytes (MKs) leads to their incomplete maturation, particularly the inability to produce proplatelets. Reduction in proplatelet formation potential is associated with a defect in actomyosin contractility, which results from inappropriate RhoA activation. This dysregulated RhoA activation was observed when MKs were plated on fibrinogen but not on other matrices (fibronectin, vitronectin, collagen 1, and von Willebrand factor), strongly suggesting a role for FLNa/αIIbβ3 interaction in the downregulation of RhoA activity. This was confirmed by experiments based on the overexpression of FLNa mutants deleted in the αIIbβ3-binding domain and the RhoA-interacting domain, respectively. Finally, pharmacological inhibition of the RhoA-associated kinase ROCK1/2 restored a normal phenotype and proplatelet formation. Overall, this work suggests a new etiology for macrothrombocytopenia, in which increased RhoA activity is associated with disrupted FLNa/αIIbβ3 interaction. Publisher9s Note: There is a Blood Commentary on this article in this issue. Key Points FLNA mutations lead to the absence of FLNa in patient MKs and a defect in proplatelet formation via RhoA overactivation. The increased RhoA activity in FLNA-mutated MKs is driven by the disruption of FLNa/αIIbβ3 interaction. Visual Abstract


  • A mutation of the human EPHB2 gene leads to a major platelet functional defect

    by Eliane Berrou, Christelle Soukaseum, Rémi Favier, Frédéric Adam, Ziane Elaib, Alexandre Kauskot, Jean-Claude Bordet, Paola Ballerini, Stephane Loyau, Miao Feng, et al.

    The ephrin transmembrane receptor (EPHR) family of tyrosine kinases is involved in platelet function. We report the first EPHB2 variant affecting platelets in two siblings (P1 and P2) from a consanguineous family with recurrent bleeding and normal platelet counts. Whole exome sequencing identified a c.2233C>T variant (missense p.R745C) of the EPHB2 gene. P1 and P2 were homozygous for this variant while their asymptomatic parents were heterozygous. The p.R745C variant within the tyrosine kinase domain was associated with defects in platelet aggregation, αIIbβ3 activation and granule secretion induced by GPCR (G protein-coupled receptors) agonists and convulxin as well as in thrombus formation on collagen under flow. In contrast, clot retraction, flow-dependent platelet adhesion and spreading on fibrinogen were only mildly affected indicating limited effects on αIIbβ3 outside-in signaling. Most importantly, Lyn, Syk and FcRγ phosphorylation, the initial steps in GPVI platelet signaling were drastically impaired in the absence of platelet-platelet contact indicating a positive role for EPHB2 in GPVI activation. Likewise platelet activation by PAR4-AP showed defective Src activation, as opposed to normal PKCs activity and Ca2+ mobilization. Overexpression of wild-type (WT) and R745C EPHB2 variant in RBL-2H3 cells (Rat Basophilic Leukemia cells) stably expressing human GPVI, confirmed EPHB2 R745C mutation impaired EPHB2 autophosphorylation, but had no effect on ephrin ligand-induced EPHB2 clustering, suggesting it did not interfere with EPHB2-ephrin-mediated cell-to-cell contact. In conclusion, this novel inherited platelet disorder affecting EPHB2 demonstrates this tyrosine kinase receptor plays an important role in platelet functions, through a cross-talk with GPVI and GPCR signaling. Key points EPHB2 tyrosine kinase receptor plays an important role in platelet function through cross-talk with GPVI and GPRC signaling. A novel EPHB2 variant causes an inherited platelet function disorder.


  • A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation

    by Alexandre Kauskot, Tiffany Pascreau, Frédéric Adam, Arnaud Bruneel, Christelle Reperant, Marc-Damien Lourenco-Rodrigues, Jean-Philippe Rosa, Rachel Petermann, Hélène Maurey, Claire Auditeau, et al.


  • Open Access

    Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets

    by Caterina Casari, David S. Paul, Sophie Susen, Cécile Lavenu-Bombled, Annie Harroche, Raymond Piatt, Kathryn O. Poe, Robert H. Lee, Marijke Bryckaert, Olivier D. Christophe, et al.

    Von Willebrand disease (VWD) type 2B is characterized by gain-of-function mutations in von Willebrand factor (VWF), enhancing its binding affinity for the platelet receptor glycoprotein (GP)Ibα. VWD type 2B patients display a bleeding tendency associated with loss of high-molecular-weight VWF multimers and variable thrombocytopenia. We recently demonstrated that a marked defect in agonist-induced activation of the small GTPase, Rap1, and integrin αIIbβ3 in VWD (p.V1316M) type 2B platelets also contributes to the bleeding tendency. Here, we investigated the molecular mechanisms underlying impaired platelet Rap1 signaling in this disease. Two distinct pathways contribute to Rap1 activation in platelets: rapid activation mediated by the calcium-sensing guanine nucleotide exchange factor CalDAG–GEF-I (CDGI) and sustained activation that is dependent on signaling by protein kinase C (PKC) and the adenosine 5′-diphosphate receptor P2Y12. To investigate which Rap1 signaling pathway is affected, we expressed VWF/p.V1316M by hydrodynamic gene transfer in wild-type and Caldaggef1−/− mice. Using αIIbβ3 integrin activation as a read-out, we demonstrate that platelet dysfunction in VWD (p.V1316M) type 2B affects PKC-mediated, but not CDGI-mediated, activation of Rap1. Consistently, we observed decreased PKC substrate phosphorylation and impaired granule release in stimulated VWD type 2B platelets. Interestingly, the defect in PKC signaling was caused by a significant increase in baseline PKC substrate phosphorylation in circulating VWD (p.V1316M) type 2B platelets, suggesting that the VWF–GPIbα interaction leads to preactivation and exhaustion of the PKC pathway. Consistent with PKC preactivation, VWD (p.V1316M) type 2B mice also exhibited marked shedding of platelet GPIbα. In summary, our studies identify altered PKC signaling as the underlying cause of platelet hypofunction in p.V1316M-associated VWD type 2B. Key Points In VWD (p.V1316M) type 2B, the VWF–GPIb interaction alters the sustained PKC-mediated pathway of Rap1 activation. VWF/p.V1316M expression in mice causes multiple platelet dysfunctions, including significant ADAM17-independent shedding of GPIbα. Visual Abstract


  • Open Access

    Kinesin-1 Is a New Actor Involved in Platelet Secretion and Thrombus Stability

    by Frédéric Adam, Alexandre Kauskot, Mathieu Kurowska, Nicolas Goudin, Isabelle Munoz, Jean-Claude Bordet, Jian-Dong Huang, Marijke Bryckaert, Alain Fischer, Delphine Borgel, et al.

    Objective—: Platelet secretion is crucial for many physiological platelet responses. Even though several regulators of the fusion machinery for secretory granule exocytosis have been identified in platelets, the underlying mechanisms are not yet fully characterized. Approach and Results—: By studying a mouse model (cKO [conditional knockout] Kif5b ) lacking Kif5b (kinesin-1 heavy chain) in its megakaryocytes and platelets, we evidenced unstable hemostasis characterized by an increase of blood loss associated to a marked tendency to rebleed in a tail-clip assay and thrombus instability in an in vivo thrombosis model. This instability was confirmed in vitro in a whole-blood perfusion assay under blood flow conditions. Aggregations induced by thrombin and collagen were also impaired in cKO Kif5b platelets. Furthermore, P-selectin exposure, PF4 (platelet factor 4) secretion, and ATP release after thrombin stimulation were impaired in cKO Kif5b platelets, highlighting the role of kinesin-1 in α-granule and dense granule secretion. Importantly, exogenous ADP rescued normal thrombin induced-aggregation in cKO Kif5b platelets, which indicates that impaired aggregation was because of defective release of ADP and dense granules. Last, we demonstrated that kinesin-1 interacts with the molecular machinery comprising the granule-associated Rab27 (Ras-related protein Rab-27) protein and the Slp4 (synaptotagmin-like protein 4/SYTL4) adaptor protein. Conclusions—: Our results indicate that a kinesin-1–dependent process plays a role for platelet function by acting into the mechanism underlying α-granule and dense granule secretion.


  • Gain-of-Function Mutation in Filamin A Potentiates Platelet Integrin α IIb β 3 Activation

    by Eliane Berrou, Frédéric Adam, Marilyne Lebret, Virginie Planche, Patricia Fergelot, Odile Issertial, Isabelle Coupry, Jean-Claude Bordet, Paquita Nurden, Dominique Bonneau, et al.

    Objective—: Dominant mutations of the X-linked filamin A ( FLNA ) gene are responsible for filaminopathies A, which are rare disorders including brain periventricular nodular heterotopia, congenital intestinal pseudo-obstruction, cardiac valves or skeleton malformations, and often macrothrombocytopenia. Approach and Results—: We studied a male patient with periventricular nodular heterotopia and congenital intestinal pseudo-obstruction, his unique X-linked FLNA allele carrying a stop codon mutation resulting in a 100–amino acid–long FLNa C-terminal extension (NP_001447.2: p.Ter2648SerextTer101 ). Platelet counts were normal, with few enlarged platelets. FLNa was detectable in all platelets but at 30% of control levels. Surprisingly, all platelet functions were significantly upregulated, including platelet aggregation and secretion, as induced by ADP, collagen, or von Willebrand factor in the presence of ristocetin, as well as thrombus formation in blood flow on a collagen or on a von Willebrand factor matrix. Most importantly, patient platelets stimulated with ADP exhibited a marked increase in α IIb β 3 integrin activation and a parallel increase in talin recruitment to β 3 , contrasting with normal Rap1 activation. These results are consistent with the mutant FLNa affecting the last step of α IIb β 3 activation. Overexpression of mutant FLNa in the HEL megakaryocytic cell line correlated with an increase (compared with wild-type FLNa) in PMA-induced fibrinogen binding to and in talin and kindlin-3 recruitment by α IIb β 3 . Conclusions—: Altogether, our results are consistent with a less binding of mutant FLNa to β 3 and the facilitated recruitment of talin by β 3 on platelet stimulation, explaining the increased α IIb β 3 activation and the ensuing gain-of-platelet functions.